Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis
Functional gastrointestinal symptoms such as abdominal pain, bloating, distension, constipation, diarrhea and flatulence have been noted in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The diversity of symptoms has meant that finding an effective treatment has been challenging with most treatments alleviating only the primary symptom. A novel treatment option for IBS and IBD currently generating much excitement is the low fermentable, oligo-, di-, mono-saccharides and polyol (FODMAP) diet. The aim of this meta-analysis was to determine the evidence of the efficacy of such a diet in the treatment of functional gastrointestinal symptoms.
Electronic databases were searched through to March 2015 to identify relevant studies. Pooled odds ratios (ORs) and 95 % confidence intervals were calculated for the effect of a low FODMAP diet on the reduction in IBS [Symptoms Severity Score (SSS)] score and increase in IBS quality of life (QOL) score for both randomized clinical trials (RCTs) and non-randomized interventions using a random-effects model.
Six RCTs and 16 non-randomized interventions were included in the analysis. There was a significant decrease in IBS SSS scores for those individuals on a low FODMAP diet in both the RCTs (OR 0.44, 95 % CI 0.25–0.76; I 2 = 35.52, p = 0.00) and non-randomized interventions (OR 0.03, 95 % CI 0.01–0.2; I 2 = 69.1, p = 0.02). In addition, there was a significant improvement in the IBS-QOL score for RCTs (OR 1.84, 95 % CI 1.12–3.03; I 2 = 0.00, p = 0.39) and for non-randomized interventions (OR 3.18, 95 % CI 1.60–6.31; I 2 = 0.00, p = 0.89). Further, following a low FODMAP diet was found to significantly reduce symptom severity for abdominal pain (OR 1.81, 95 % CI 1.13–2.88; I 2 = 0.00, p = 0.56), bloating (OR 1.75, 95 % CI 1.07–2.87; I 2 = 0.00, p = 0.45) and overall symptoms (OR 1.81, 95 % CI 1.11–2.95; I 2 = 0.00, p = 0.4) in the RCTs. In the non-randomized interventions similar findings were observed.
The present meta-analysis supports the efficacy of a low FODMAP diet in the treatment of functional gastrointestinal symptoms. Further research should ensure studies include dietary adherence, and more studies looking at greater number of patients and long-term adherence to a low FODMAP diet need to be conducted.
KeywordsFODMAP Diet Functional gastrointestinal disorders FGID Symptoms Meta-analysis
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Russo MW, Gaynes BN, Drossman DA (1999) A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 29(339):43Google Scholar
- 2.Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM (2009) An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104:S1–S35Google Scholar
- 6.Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM (2009) American college of gastroenterology task force on irritable bowel syndrome—an evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104(Suppl 1):S1–S35Google Scholar
- 11.Parker K, Salas M, Nwosu VC (2010) High fructose corn syrup: production, uses and public health concerns. Biotechnol Mol Biol Rev 5(5):71–78Google Scholar
- 12.Barrett JS, Gearry RB, Muir JG, Irving PM, Rose R, Rosella O, Haines ML, Shepherd SJ, Gibson PR (2010) Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 31(8):874Google Scholar
- 15.Huamán JW, Felip A, Guedea E, Jansana M, Videla S, Saperas E (2014) The diet low in fermentable carbohydrates short chain and polyols improves symptoms in patients with functional gastrointestinal disorders in Spain. Gastroenterol Hepatol 6(14):00245Google Scholar
- 24.Harvie R, Schultz M, Chisholm A (2013) A reduction in FODMAP intake correlates strongly with a reduction in IBS symptoms–the FIBS study. J Gastroenterol Hepatol 28(Suppl. 3):23–693Google Scholar
- 35.Van Megen F, Kahrs GE (2014) Effects of a FODMAP-restricted diet on irritable bowel symptoms in patients with inflammatory bowel disease. United Eur Gastroenterol J 2(Suppl 1):P0342Google Scholar
- 36.Chevillat D, Neff S, Maghdessian R, Kiss C, Maissen S (2014) P091: L’approche FODMAP améliore la symptomatologie gastro-intestinale chez les patients adultes souffrant d’un syndrome de l’intestin irritable: une étude pilote. Nutrition Clinique et Métabolisme. UEG Week 28: S116Google Scholar
- 37.Zanini B, Marullo M, Ricci C, Lanzarotto F, Lanzini A (2014) Sa1989 non celiac gluten sensitivity (NCGS) is outnumbered by FODMAPs sensitivity in patients spontaneously adhering to gluten free diet (GFD): a two stage double blind prospective study. Gastroenterology 146(5):S-348CrossRefGoogle Scholar
- 39.Mazzawi T, Hausken T, Gundersen D, El-Salhy M (2013) Effects of dietary guidance on the symptoms, quality of life and habitual dietary intake of patients with irritable bowel syndrome. Mol Med Rep 8(3):845–852Google Scholar
- 41.Azpiroz F, Guyonnet D, Donazzolo Y, Gendre D, Tanguy J, Guarner F (2014) Digestive symptoms in healthy people and subjects with irritable bowel syndrome: validation of symptom frequency questionnaire. J Clin Gastroenterol 1Google Scholar
- 46.James SL et al (2009) FODMAP but not fibre intake is associated with IBS-like symptoms in patients with IBD. J Gastroenterol Hepatol 24:A313–A314Google Scholar
- 47.Rome F (2006) Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointest Liver Dis 15(3):307–312Google Scholar
- 48.Buono JL, Tourkodimitris S, Sarocco P, Johnston JM, Carson RT (2014) Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits 7(5):289Google Scholar
- 55.Böhn L, Störsrud S, LiIjebo T, Collin L, Törnblom H, Simrén M (2014) A Multi-center, randomized, controlled, single-blind, comparative trial: low-FODMAP diet versus traditional dietary advice in IBS. United Eur Gastroenterol J 2(1S):A1–A131Google Scholar